Eli Lilly and Company revealed its latest data from multiple trials of CYRAMZA (ramucirumab) during the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago. The results presented were taken from a Phase II study of non-small cell lung cancer (NSCLC) patients in Japan and from global Phase III studies of CYRAMZA in non-small cell lung, gastric and hepatocellular cancers.
CYRAMZA is an antiangiogenic therapy consisting of a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that specifically binds and stops the activation of VEGF Receptor 2 by blocking ligation between this receptor and its ligands VEGF-A, VEGF-C, and VEGF-D. CYRAMZA has already proved in vivo its capacity to inhibit angiogenesis in animal models of cancer.
“In just over a year, CYRAMZA received four full FDA approvals in advanced or metastatic forms of three of the world’s most common and deadly cancers – gastric, non-small cell lung, and colorectal. We believe this is a first for an oncology product, and our CYRAMZA ASCO disclosures supplement these clinical advances. Further data at the meeting show how we are investigating CYRAMZA in other difficult-to-treat cancers, such as hepatocellular carcinoma, to help address additional unmet needs for people battling this devastating disease,” said Richard Gaynor, Lilly Oncology’s representative.
Results from the Phase III REVEL trial showed that patients treated with ramucirumab-plus-docetaxel had a median progression-free survival (PFS) of 5.22 months versus 4.21 months for those on placebo-plus-docetaxel. Data from the REGARD and RAINBOW trials (2 Phase III trials) allowed researchers to develop a strategy to better support clinical decision-making and future planning.
CYRAMZA (ramucirumab) is now approved in the United States by the U. S. Food and Drug Administration to be used combined with docetaxel (chemotherapy) to address those with metastatic non-small cell lung cancer (NSCLC) which has progressed even after platinum-based chemotherapy. It is also approved to be used both as a single agent and combined with paclitaxel (chemotherapy) to address the treatment to those suffering with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. Furthermore, it can also be used with FOLFIRI (chemotherapy) for those with metastatic colorectal cancer (mCRC).
Other studies are planned to assess CYRAMZA both as a single agent and in combination with other anti-cancer therapies that might treat several types of tumors.
